人福医药：关于HWH217片获得药物临床试验批准通知书的公告

Core Viewpoint - The company, Renfu Pharmaceutical, announced that its wholly-owned subsidiary, Hubei Biopharmaceutical Industry Technology Research Institute, has received approval from the National Medical Products Administration for the clinical trial of HWH217 tablets [2] Group 1 - The approval is a significant milestone for the company as it progresses in the development of HWH217 tablets [2] - The clinical trial approval indicates the company's commitment to advancing its pharmaceutical research and development efforts [2] - This development may enhance the company's position in the biopharmaceutical industry [2]